By Sriparna Roy (Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Set to enter larger trial across 5 countries, it works by permanently turning off gene that causes high bad cholesterol ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

An experimental drug developed at Duke University School of Medicine could offer powerful pain relief without the dangerous ...

An experimental drug known as ulefnersen has shown remarkable efficacy in treating a rare, aggressive form of ALS ...

Learn how a new genetic therapy could transform treatment for rare ALS—keep reading for remarkable patient outcomes.

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...